Literature DB >> 8750894

Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study.

K A Harrington1, S J Augood, R L Faull, P J McKenna, P C Emson.   

Abstract

The cellular expression of the mRNAs encoding the dopamine D1 receptor, dopamine D2 receptor and the neuropeptides enkephalin and substance P was determined in fresh frozen sections of human post-mortem caudate nucleus from control and schizophrenic brains using the technique of radioactive in situ hybridisation coupled with computer-assisted image analysis. Measurements of silver grain densities and mean cross-sectional somatic areas revealed no significant differences in the expression of any of these four gene transcripts. Further, cell count estimates revealed that each of these four mRNAs was expressed by approximately 20% of caudate cells (neurones and glia) in both control and schizophrenic tissue. These data demonstrate that the cellular expression of the dopamine D1 and D2 receptors and the neuropeptides enkephalin and substance P mRNAs are stable post mortem and that the relative cellular abundance of these mRNAs is not altered in the caudate nucleus of schizophrenic brains when compared to controls. These findings draw into focus the possible sites of action of clinically prescribed neuroleptics and suggest that chronic neuroleptic treatment of patients displaying negative schizophrenic symptoms may 're-set' an underlying neurochemical imbalance within the caudate nucleus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750894     DOI: 10.1016/0169-328x(95)00169-s

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  4 in total

1.  Pain sensitivity is altered in animals after subchronic ketamine treatment.

Authors:  Axel Becker; Gisela Grecksch; Helmut Schröder
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

2.  Evidence for disruption of sphingolipid metabolism in schizophrenia.

Authors:  Sujatha Narayan; Steven R Head; Timothy J Gilmartin; Brian Dean; Elizabeth A Thomas
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

Review 3.  Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review.

Authors:  M O Trépanier; K E Hopperton; R Mizrahi; N Mechawar; R P Bazinet
Journal:  Mol Psychiatry       Date:  2016-06-07       Impact factor: 15.992

4.  Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging.

Authors:  Abhishekh H Ashok; Jim Myers; Tiago Reis Marques; Eugenii A Rabiner; Oliver D Howes
Journal:  Nat Commun       Date:  2019-10-03       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.